# C_2015306EN.01000601.xml

| 17.9.2015 | EN | Official Journal of the European Union | C 306/6 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/6

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014

(2015/C 306/08)

Subcommittee I on the free movement of goods

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2014, at their meeting on 12 December 2014:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

Annex I

List of new marketing authorisations

Annex II

Annex II

List of renewed marketing authorisations

Annex III

Annex III

List of extended marketing authorisations

Annex IV

Annex IV

List of withdrawn marketing authorisations

Annex V

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/06/361 | Luminity | Iceland | 5.6.2014 |
| EU/1/06/367 | Diacomit | Liechtenstein | 28.2.2014 |
| EU/1/12/767 | Nimenrix | Liechtenstein | 30.6.2014 |
| EU/1/13/834 | Zoledronic Acid Accord | Iceland | 7.2.2014 |
| EU/1/13/834 | Zoledronic acid Accord | Liechtenstein | 28.2.2014 |
| EU/1/13/834 | Zoledronic acid Accord | Norway | 29.1.2014 |
| EU/1/13/837 | Tecfidera | Iceland | 11.2.2014 |
| EU/1/13/837 | Tecfidera | Liechtenstein | 28.2.2014 |
| EU/1/13/837 | Tecfidera | Norway | 5.2.2014 |
| EU/1/13/856 | Lonquex | Liechtenstein | 30.4.2014 |
| EU/1/13/875 | Deltyba | Iceland | 23.5.2014 |
| EU/1/13/875 | Deltyba | Liechtenstein | 30.6.2014 |
| EU/1/13/875 | Deltyba | Norway | 9.5.2014 |
| EU/1/13/887 | Fluenz Tetra | Iceland | 3.1.2014 |
| EU/1/13/887 | Fluenz Tetra | Liechtenstein | 28.2.2014 |
| EU/1/13/887 | Fluenz Tetra | Norway | 9.1.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Iceland | 15.1.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Liechtenstein | 28.2.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Norway | 21.1.2014 |
| EU/1/13/890 | Cometriq | Iceland | 8.4.2014 |
| EU/1/13/890 | Cometriq | Liechtenstein | 30.4.2014 |
| EU/1/13/890 | Cometriq | Norway | 11.4.2014 |
| EU/1/13/891 | Brintellix | Iceland | 13.1.2014 |
| EU/1/13/891 | Brintellix | Liechtenstein | 28.2.2014 |
| EU/1/13/891 | Brintellix | Norway | 17.1.2014 |
| EU/1/13/892 | Tivicay | Iceland | 6.2.2014 |
| EU/1/13/892 | Tivicay | Liechtenstein | 28.2.2014 |
| EU/1/13/892 | Tivicay | Norway | 28.1.2014 |
| EU/1/13/893 | Opsumit | Iceland | 14.1.2014 |
| EU/1/13/893 | Opsumit | Norway | 17.1.2014 |
| EU/1/13/894 | Sovaldi | Iceland | 6.2.2014 |
| EU/1/13/894 | Sovaldi | Liechtenstein | 28.2.2014 |
| EU/1/13/894 | Sovaldi | Norway | 29.1.2014 |
| EU/1/13/895 | Cholic acid FGK | Iceland | 15.4.2014 |
| EU/1/13/895 | Cholic Acid FGK | Liechtenstein | 30.4.2014 |
| EU/1/13/895 | Kolsyre FGK | Norway | 28.4.2014 |
| EU/1/13/896 | Para-aminosalicylic acid Lucane | Iceland | 7.5.2014 |
| EU/1/13/896 | Para-aminosalicylic acid Lucane | Liechtenstein | 30.4.2014 |
| EU/1/13/896 | Granupas | Norway | 13.5.2014 |
| EU/1/13/898 | Anoro | Liechtenstein | 30.6.2014 |
| EU/1/13/899 | Laventair | Liechtenstein | 30.6.2014 |
| EU/1/13/900 | Xigduo | Iceland | 6.2.2014 |
| EU/1/13/900 | Xigduo | Liechtenstein | 28.2.2014 |
| EU/1/13/900 | Xigduo | Norway | 28.1.2014 |
| EU/1/13/901 | SIRTURO | Iceland | 4.4.2014 |
| EU/1/13/901 | Sirturo | Liechtenstein | 30.4.2014 |
| EU/1/13/901 | Sirturo | Norway | 14.3.2014 |
| EU/1/13/904 | Mirvaso | Iceland | 20.3.2014 |
| EU/1/13/904 | Mirvaso | Liechtenstein | 28.2.2014 |
| EU/1/13/904 | Mirvaso | Norway | 17.3.2014 |
| EU/1/13/905 | IZBA | Iceland | 18.3.2014 |
| EU/1/13/905 | Izba | Liechtenstein | 28.2.2014 |
| EU/1/13/905 | Izba | Norway | 17.3.2014 |
| EU/1/13/906 | Neuraceq | Iceland | 20.3.2014 |
| EU/1/13/906 | Neuraceq | Liechtenstein | 28.2.2014 |
| EU/1/13/906 | Neuraceq | Norway | 24.3.2014 |
| EU/1/13/907 | Adempas | Iceland | 8.4.2014 |
| EU/1/13/907 | Adempas | Liechtenstein | 30.4.2014 |
| EU/1/13/907 | Adempas | Norway | 7.4.2014 |
| EU/1/13/908 | Eperzan | Iceland | 9.4.2014 |
| EU/1/13/908 | Eperzan | Liechtenstein | 30.4.2014 |
| EU/1/13/908 | Eperzan | Norway | 15.4.2014 |
| EU/1/13/909 | Bemfola | Iceland | 14.4.2014 |
| EU/1/13/909 | Bemfola | Liechtenstein | 30.4.2014 |
| EU/1/13/909 | Bemfola | Norway | 25.4.2014 |
| EU/1/14/898 | ANORO | Iceland | 27.5.2014 |
| EU/1/14/898 | Anoro | Norway | 28.5.2014 |
| EU/1/14/899 | Laventair | Iceland | 27.5.2014 |
| EU/1/14/899 | Laventair | Norway | 4.6.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Iceland | 14.4.2014 |
| EU/1/14/911 | Rivastigmin 3M Health Care Ltd. | Liechtenstein | 30.4.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Norway | 14.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Iceland | 10.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Liechtenstein | 30.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Norway | 15.4.2014 |
| EU/1/14/913 | Latuda | Iceland | 8.4.2014 |
| EU/1/14/913 | Latuda | Liechtenstein | 30.4.2014 |
| EU/1/14/913 | Latuda | Norway | 8.4.2014 |
| EU/1/14/914 | Vimizim | Iceland | 23.5.2014 |
| EU/1/14/914 | Vimizim | Liechtenstein | 30.6.2014 |
| EU/1/14/914 | Vimizim | Norway | 23.5.2014 |
| EU/1/14/915 | Ebilfumin | Iceland | 5.6.2014 |
| EU/1/14/915 | Ebilfumin | Liechtenstein | 30.6.2014 |
| EU/1/14/915 | Ebilfumin | Norway | 18.6.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Iceland | 7.5.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Liechtenstein | 30.4.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Norway | 13.5.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Liechtenstein | 30.6.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Norway | 21.5.2014 |
| EU/1/14/918 | Vokanamet | Iceland | 12.5.2014 |
| EU/1/14/918 | Vokanamet | Liechtenstein | 30.4.2014 |
| EU/1/14/918 | Vokanamet | Norway | 29.4.2014 |
| EU/1/14/919 | Hemangiol | Iceland | 12.5.2014 |
| EU/1/14/919 | Hemangiol | Liechtenstein | 30.4.2014 |
| EU/1/14/919 | Hemangiol | Norway | 8.5.2014 |
| EU/1/14/920 | DuoResp Spiromax | Iceland | 22.5.2014 |
| EU/1/14/920 | DuoResp Spiromax | Liechtenstein | 30.6.2014 |
| EU/1/14/920 | DuoResp Spiromax | Norway | 22.5.2014 |
| EU/1/14/921 | BiResp Spiromax | Iceland | 23.5.2014 |
| EU/1/14/921 | BiResp Spiromax | Liechtenstein | 30.6.2014 |
| EU/1/14/921 | BiResp Spiromax | Norway | 15.5.2014 |
| EU/1/14/922 | Incruse | Iceland | 22.5.2014 |
| EU/1/14/922 | Incruse | Liechtenstein | 30.6.2014 |
| EU/1/14/922 | Incruse | Norway | 22.5.2014 |
| EU/1/14/923 | Entyvio | Iceland | 5.6.2014 |
| EU/1/14/923 | Entyvio | Liechtenstein | 30.6.2014 |
| EU/1/14/923 | Entyvio | Norway | 17.6.2014 |
| EU/1/14/924 | OLYSIO | Iceland | 5.6.2014 |
| EU/1/14/924 | OLYSIO | Liechtenstein | 30.6.2014 |
| EU/1/14/924 | Olysio | Norway | 23.5.2014 |
| EU/1/14/928 | Sylvant | Iceland | 5.6.2014 |
| EU/1/14/928 | Sylvant | Liechtenstein | 30.6.2014 |
| EU/1/14/928 | Sylvant | Norway | 19.6.2014 |
| EU/1/14/929 | Revinty Ellipta | Iceland | 26.5.2014 |
| EU/1/14/929 | Revinty Ellipta | Liechtenstein | 30.6.2014 |
| EU/1/14/929 | Revinty Ellipta | Norway | 15.5.2014 |
| EU/1/14/930 | Jardiance | Iceland | 5.6.2014 |
| EU/1/14/930 | Jardiance | Liechtenstein | 30.6.2014 |
| EU/1/14/930 | Jardiance | Norway | 28.5.2014 |
| EU/2/09/096 | Leucogen | Liechtenstein | 30.6.2014 |
| EU/2/09/103 | Respiporc Flu3 | Norway | 13.2.2014 |
| EU/2/12/138 | RevitaCAM | Liechtenstein | 30.4.2014 |
| EU/2/12/140 | Poulvac E.coli | Norway | 7.4.2014 |
| EU/2/13/151 | Equilis West Nile | Norway | 7.4.2014 |
| EU/2/13/153 | Aftovaxpur Doe | Norway | 29.1.2014 |
| EU/2/13/154 | Apoquel | Norway | 21.1.2014 |
| EU/2/13/155 | Trifexis | Norway | 4.4.2014 |
| EU/2/13/156 | Vectra 3D | Norway | 4.4.2014 |
| EU/2/13/157 | Broadline | Norway | 24.3.2014 |
| EU/2/13/158 | Bravecto | Iceland | 28.2.2014 |
| EU/2/13/158 | Bravecto | Liechtenstein | 28.2.2014 |
| EU/2/13/158 | Bravecto | Norway | 21.3.2014 |
| EU/2/13/159 | NexGard | Iceland | 28.2.2014 |
| EU/2/13/159 | NexGard | Liechtenstein | 28.2.2014 |
| EU/2/13/159 | NexGard | Norway | 4.4.2014 |
| EU/2/13/160 | Fungitraxx | Iceland | 9.4.2014 |
| EU/2/13/160 | Fungitraxx | Liechtenstein | 30.4.2014 |
| EU/2/13/160 | Fungitraxx | Norway | 15.4.2014 |
| EU/2/14/161 | Equisolon | Iceland | 9.4.2014 |
| EU/2/14/161 | Equisolon | Liechtenstein | 30.4.2014 |
| EU/2/14/161 | Equisolon | Norway | 15.4.2014 |
| EU/2/14/162 | Parvoduk | Iceland | 9.5.2014 |
| EU/2/14/162 | Parvoduk | Norway | 6.6.2014 |
| EU/2/14/163 | Versican Plus DHPPi/L4R | Iceland | 6.6.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Iceland | 6.6.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Liechtenstein | 30.6.2014 |
| EU/2/14/165 | Vectra Felis | Iceland | 18.6.2014 |
| EU/2/14/165 | Vectra Felis | Liechtenstein | 30.6.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/06/361

Luminity

Iceland

5.6.2014

EU/1/06/367

Diacomit

Liechtenstein

28.2.2014

EU/1/12/767

Nimenrix

Liechtenstein

30.6.2014

EU/1/13/834

Zoledronic Acid Accord

Iceland

7.2.2014

EU/1/13/834

Zoledronic acid Accord

Liechtenstein

28.2.2014

EU/1/13/834

Zoledronic acid Accord

Norway

29.1.2014

EU/1/13/837

Tecfidera

Iceland

11.2.2014

EU/1/13/837

Tecfidera

Liechtenstein

28.2.2014

EU/1/13/837

Tecfidera

Norway

5.2.2014

EU/1/13/856

Lonquex

Liechtenstein

30.4.2014

EU/1/13/875

Deltyba

Iceland

23.5.2014

EU/1/13/875

Deltyba

Liechtenstein

30.6.2014

EU/1/13/875

Deltyba

Norway

9.5.2014

EU/1/13/887

Fluenz Tetra

Iceland

3.1.2014

EU/1/13/887

Fluenz Tetra

Liechtenstein

28.2.2014

EU/1/13/887

Fluenz Tetra

Norway

9.1.2014

EU/1/13/889

Levetiracetam Hospira

Iceland

15.1.2014

EU/1/13/889

Levetiracetam Hospira

Liechtenstein

28.2.2014

EU/1/13/889

Levetiracetam Hospira

Norway

21.1.2014

EU/1/13/890

Cometriq

Iceland

8.4.2014

EU/1/13/890

Cometriq

Liechtenstein

30.4.2014

EU/1/13/890

Cometriq

Norway

11.4.2014

EU/1/13/891

Brintellix

Iceland

13.1.2014

EU/1/13/891

Brintellix

Liechtenstein

28.2.2014

EU/1/13/891

Brintellix

Norway

17.1.2014

EU/1/13/892

Tivicay

Iceland

6.2.2014

EU/1/13/892

Tivicay

Liechtenstein

28.2.2014

EU/1/13/892

Tivicay

Norway

28.1.2014

EU/1/13/893

Opsumit

Iceland

14.1.2014

EU/1/13/893

Opsumit

Norway

17.1.2014

EU/1/13/894

Sovaldi

Iceland

6.2.2014

EU/1/13/894

Sovaldi

Liechtenstein

28.2.2014

EU/1/13/894

Sovaldi

Norway

29.1.2014

EU/1/13/895

Cholic acid FGK

Iceland

15.4.2014

EU/1/13/895

Cholic Acid FGK

Liechtenstein

30.4.2014

EU/1/13/895

Kolsyre FGK

Norway

28.4.2014

EU/1/13/896

Para-aminosalicylic acid Lucane

Iceland

7.5.2014

EU/1/13/896

Para-aminosalicylic acid Lucane

Liechtenstein

30.4.2014

EU/1/13/896

Granupas

Norway

13.5.2014

EU/1/13/898

Anoro

Liechtenstein

30.6.2014

EU/1/13/899

Laventair

Liechtenstein

30.6.2014

EU/1/13/900

Xigduo

Iceland

6.2.2014

EU/1/13/900

Xigduo

Liechtenstein

28.2.2014

EU/1/13/900

Xigduo

Norway

28.1.2014

EU/1/13/901

SIRTURO

Iceland

4.4.2014

EU/1/13/901

Sirturo

Liechtenstein

30.4.2014

EU/1/13/901

Sirturo

Norway

14.3.2014

EU/1/13/904

Mirvaso

Iceland

20.3.2014

EU/1/13/904

Mirvaso

Liechtenstein

28.2.2014

EU/1/13/904

Mirvaso

Norway

17.3.2014

EU/1/13/905

IZBA

Iceland

18.3.2014

EU/1/13/905

Izba

Liechtenstein

28.2.2014

EU/1/13/905

Izba

Norway

17.3.2014

EU/1/13/906

Neuraceq

Iceland

20.3.2014

EU/1/13/906

Neuraceq

Liechtenstein

28.2.2014

EU/1/13/906

Neuraceq

Norway

24.3.2014

EU/1/13/907

Adempas

Iceland

8.4.2014

EU/1/13/907

Adempas

Liechtenstein

30.4.2014

EU/1/13/907

Adempas

Norway

7.4.2014

EU/1/13/908

Eperzan

Iceland

9.4.2014

EU/1/13/908

Eperzan

Liechtenstein

30.4.2014

EU/1/13/908

Eperzan

Norway

15.4.2014

EU/1/13/909

Bemfola

Iceland

14.4.2014

EU/1/13/909

Bemfola

Liechtenstein

30.4.2014

EU/1/13/909

Bemfola

Norway

25.4.2014

EU/1/14/898

ANORO

Iceland

27.5.2014

EU/1/14/898

Anoro

Norway

28.5.2014

EU/1/14/899

Laventair

Iceland

27.5.2014

EU/1/14/899

Laventair

Norway

4.6.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Iceland

14.4.2014

EU/1/14/911

Rivastigmin 3M Health Care Ltd.

Liechtenstein

30.4.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Norway

14.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Iceland

10.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Liechtenstein

30.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Norway

15.4.2014

EU/1/14/913

Latuda

Iceland

8.4.2014

EU/1/14/913

Latuda

Liechtenstein

30.4.2014

EU/1/14/913

Latuda

Norway

8.4.2014

EU/1/14/914

Vimizim

Iceland

23.5.2014

EU/1/14/914

Vimizim

Liechtenstein

30.6.2014

EU/1/14/914

Vimizim

Norway

23.5.2014

EU/1/14/915

Ebilfumin

Iceland

5.6.2014

EU/1/14/915

Ebilfumin

Liechtenstein

30.6.2014

EU/1/14/915

Ebilfumin

Norway

18.6.2014

EU/1/14/916

Pregabalin Pfizer

Iceland

7.5.2014

EU/1/14/916

Pregabalin Pfizer

Liechtenstein

30.4.2014

EU/1/14/916

Pregabalin Pfizer

Norway

13.5.2014

EU/1/14/917

Ulunar Breezhaler

Liechtenstein

30.6.2014

EU/1/14/917

Ulunar Breezhaler

Norway

21.5.2014

EU/1/14/918

Vokanamet

Iceland

12.5.2014

EU/1/14/918

Vokanamet

Liechtenstein

30.4.2014

EU/1/14/918

Vokanamet

Norway

29.4.2014

EU/1/14/919

Hemangiol

Iceland

12.5.2014

EU/1/14/919

Hemangiol

Liechtenstein

30.4.2014

EU/1/14/919

Hemangiol

Norway

8.5.2014

EU/1/14/920

DuoResp Spiromax

Iceland

22.5.2014

EU/1/14/920

DuoResp Spiromax

Liechtenstein

30.6.2014

EU/1/14/920

DuoResp Spiromax

Norway

22.5.2014

EU/1/14/921

BiResp Spiromax

Iceland

23.5.2014

EU/1/14/921

BiResp Spiromax

Liechtenstein

30.6.2014

EU/1/14/921

BiResp Spiromax

Norway

15.5.2014

EU/1/14/922

Incruse

Iceland

22.5.2014

EU/1/14/922

Incruse

Liechtenstein

30.6.2014

EU/1/14/922

Incruse

Norway

22.5.2014

EU/1/14/923

Entyvio

Iceland

5.6.2014

EU/1/14/923

Entyvio

Liechtenstein

30.6.2014

EU/1/14/923

Entyvio

Norway

17.6.2014

EU/1/14/924

OLYSIO

Iceland

5.6.2014

EU/1/14/924

OLYSIO

Liechtenstein

30.6.2014

EU/1/14/924

Olysio

Norway

23.5.2014

EU/1/14/928

Sylvant

Iceland

5.6.2014

EU/1/14/928

Sylvant

Liechtenstein

30.6.2014

EU/1/14/928

Sylvant

Norway

19.6.2014

EU/1/14/929

Revinty Ellipta

Iceland

26.5.2014

EU/1/14/929

Revinty Ellipta

Liechtenstein

30.6.2014

EU/1/14/929

Revinty Ellipta

Norway

15.5.2014

EU/1/14/930

Jardiance

Iceland

5.6.2014

EU/1/14/930

Jardiance

Liechtenstein

30.6.2014

EU/1/14/930

Jardiance

Norway

28.5.2014

EU/2/09/096

Leucogen

Liechtenstein

30.6.2014

EU/2/09/103

Respiporc Flu3

Norway

13.2.2014

EU/2/12/138

RevitaCAM

Liechtenstein

30.4.2014

EU/2/12/140

Poulvac E.coli

Norway

7.4.2014

EU/2/13/151

Equilis West Nile

Norway

7.4.2014

EU/2/13/153

Aftovaxpur Doe

Norway

29.1.2014

EU/2/13/154

Apoquel

Norway

21.1.2014

EU/2/13/155

Trifexis

Norway

4.4.2014

EU/2/13/156

Vectra 3D

Norway

4.4.2014

EU/2/13/157

Broadline

Norway

24.3.2014

EU/2/13/158

Bravecto

Iceland

28.2.2014

EU/2/13/158

Bravecto

Liechtenstein

28.2.2014

EU/2/13/158

Bravecto

Norway

21.3.2014

EU/2/13/159

NexGard

Iceland

28.2.2014

EU/2/13/159

NexGard

Liechtenstein

28.2.2014

EU/2/13/159

NexGard

Norway

4.4.2014

EU/2/13/160

Fungitraxx

Iceland

9.4.2014

EU/2/13/160

Fungitraxx

Liechtenstein

30.4.2014

EU/2/13/160

Fungitraxx

Norway

15.4.2014

EU/2/14/161

Equisolon

Iceland

9.4.2014

EU/2/14/161

Equisolon

Liechtenstein

30.4.2014

EU/2/14/161

Equisolon

Norway

15.4.2014

EU/2/14/162

Parvoduk

Iceland

9.5.2014

EU/2/14/162

Parvoduk

Norway

6.6.2014

EU/2/14/163

Versican Plus DHPPi/L4R

Iceland

6.6.2014

EU/2/14/164

Versican Plus DHPPi/L4

Iceland

6.6.2014

EU/2/14/164

Versican Plus DHPPi/L4

Liechtenstein

30.6.2014

EU/2/14/165

Vectra Felis

Iceland

18.6.2014

EU/2/14/165

Vectra Felis

Liechtenstein

30.6.2014

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/03/265 | Bonviva | Iceland | 9.1.2014 |
| EU/1/03/265 | Bonviva | Norway | 16.1.2014 |
| EU/1/03/265 | Bonviva | Liechtenstein | 28.2.2014 |
| EU/1/03/271 | Advate | Iceland | 15.1.2014 |
| EU/1/03/271 | Advate | Norway | 17.1.2014 |
| EU/1/03/271 | Advate | Liechtenstein | 28.2.2014 |
| EU/1/04/274 | Velcade | Norway | 30.1.2014 |
| EU/1/04/274 | Velcade | Iceland | 5.2.2014 |
| EU/1/04/287 | Osseor | Norway | 18.6.2014 |
| EU/1/04/287 | Osseor | Liechtenstein | 30.6.2014 |
| EU/1/04/288 | Protelos | Norway | 18.6.2014 |
| EU/1/04/288 | Protelos | Liechtenstein | 30.6.2014 |
| EU/1/04/289 | Angiox | Liechtenstein | 30.6.2014 |
| EU/1/06/367 | Diacomit | Norway | 17.1.2014 |
| EU/1/06/367 | Diacomit | Iceland | 15.1.2014 |
| EU/1/07/423 | Vectibix | Liechtenstein | 28.2.2014 |
| EU/1/07/423 | Vectibix | Norway | 17.3.2014 |
| EU/1/07/423 | Vectibix | Iceland | 17.3.2014 |
| EU/1/07/436 | Isentress | Norway | 22.5.2014 |
| EU/1/07/436 | Isentress | Iceland | 26.5.2014 |
| EU/1/07/436 | Isentress | Liechtenstein | 30.6.2014 |
| EU/1/07/440 | Tyverb | Iceland | 19.3.2014 |
| EU/1/07/440 | Tyverb | Norway | 19.3.2014 |
| EU/1/07/440 | Tyverb | Liechtenstein | 30.4.2014 |
| EU/1/08/497 | Nplate | Iceland | 14.1.2014 |
| EU/1/08/497 | Nplate | Norway | 17.1.2014 |
| EU/1/08/497 | Nplate | Liechtenstein | 28.2.2014 |
| EU/1/08/501 | Ixiaro | Iceland | 18.3.2014 |
| EU/1/08/501 | Ixiaro | Norway | 25.3.2014 |
| EU/1/08/501 | Ixiaro | Liechtenstein | 30.4.2014 |
| EU/1/08/502 | Mepact | Iceland | 13.1.2014 |
| EU/1/08/502 | Mepact | Norway | 16.1.2014 |
| EU/1/08/502 | Mepact | Liechtenstein | 28.2.2014 |
| EU/1/09/508 | Synflorix | Liechtenstein | 28.2.2014 |
| EU/1/09/508 | Synflorix | Iceland | 18.3.2014 |
| EU/1/09/508 | Synflorix | Norway | 24.3.2014 |
| EU/1/09/509 | Ribavirin Teva | Norway | 29.1.2014 |
| EU/1/09/509 | Ribavirin Teva | Iceland | 6.2.2014 |
| EU/1/09/509 | Ribavirin Teva | Liechtenstein | 28.2.2014 |
| EU/1/09/510 | Fertavid | Liechtenstein | 28.2.2014 |
| EU/1/09/510 | Fertavid | Norway | 17.3.2014 |
| EU/1/09/510 | Fertavid | Iceland | 18.3.2014 |
| EU/1/09/511 | Conbriza | Norway | 17.3.2014 |
| EU/1/09/512 | Removab | Iceland | 10.1.2014 |
| EU/1/09/512 | Removab | Norway | 20.1.2014 |
| EU/1/09/512 | Removab | Liechtenstein | 28.2.2014 |
| EU/1/09/514 | Zebinix | Norway | 3.2.2014 |
| EU/1/09/514 | Zebinix | Iceland | 5.2.2014 |
| EU/1/09/514 | Zebinix | Liechtenstein | 28.2.2014 |
| EU/1/09/515 | CONTROLOC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/515 | CONTROLOC Control | Iceland | 18.3.2014 |
| EU/1/09/515 | Controloc Control | Norway | 20.3.2014 |
| EU/1/09/516 | SOMAC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/516 | SOMAC Control | Iceland | 18.3.2014 |
| EU/1/09/516 | Somac Control | Norway | 20.3.2014 |
| EU/1/09/517 | PANTOZOL Control | Liechtenstein | 28.2.2014 |
| EU/1/09/517 | PANTOZOL Control | Iceland | 18.3.2014 |
| EU/1/09/517 | Pantozol Control | Norway | 20.3.2014 |
| EU/1/09/518 | PANTECTA Control | Liechtenstein | 28.2.2014 |
| EU/1/09/518 | PANTECTA Control | Iceland | 18.3.2014 |
| EU/1/09/518 | Pantecta Control | Norway | 20.3.2014 |
| EU/1/09/519 | PANTOLOC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/519 | PANTOLOC Control | Iceland | 18.3.2014 |
| EU/1/09/519 | Pantoloc Control | Norway | 20.3.2014 |
| EU/1/09/521 | Renvela | Iceland | 10.4.2014 |
| EU/1/09/521 | Renvela | Norway | 23.4.2014 |
| EU/1/09/521 | Renvela | Liechtenstein | 30.4.2014 |
| EU/1/09/522 | ellaOne | Iceland | 10.4.2014 |
| EU/1/09/522 | ellaOne | Norway | 25.4.2014 |
| EU/1/09/522 | ellaOne | Liechtenstein | 30.4.2014 |
| EU/1/09/523 | Modigraf | Liechtenstein | 28.2.2014 |
| EU/1/09/523 | Modigraf | Iceland | 12.3.2014 |
| EU/1/09/523 | Modigraf | Norway | 17.3.2014 |
| EU/1/09/524 | Qutenza | Liechtenstein | 30.4.2014 |
| EU/1/09/524 | Qutenza | Norway | 9.5.2014 |
| EU/1/09/524 | Qutenza | Iceland | 14.5.2014 |
| EU/1/09/525 | Nimvastid | Norway | 29.1.2014 |
| EU/1/09/525 | Nimvastid | Iceland | 5.2.2014 |
| EU/1/09/525 | Nimvastid | Liechtenstein | 28.2.2014 |
| EU/1/09/526 | Iressa | Iceland | 9.5.2014 |
| EU/1/09/526 | Iressa | Norway | 20.5.2014 |
| EU/1/09/526 | Iressa | Liechtenstein | 30.6.2014 |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Norway | 29.1.2014 |
| EU/1/09/527 | Ribavirin Teva Pharma B.V. | Iceland | 6.2.2014 |
| EU/1/09/528 | Peyona | Norway | 17.3.2014 |
| EU/1/09/528 | Peyona | Iceland | 19.3.2014 |
| EU/1/09/528 | Peyona | Liechtenstein | 30.4.2014 |
| EU/1/09/529 | Victoza | Norway | 25.4.2014 |
| EU/1/09/529 | Victoza | Liechtenstein | 30.4.2014 |
| EU/1/09/529 | Victoza | Iceland | 9.5.2014 |
| EU/1/09/530 | Repaglinide Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/531 | Instanyl | Norway | 29.4.2014 |
| EU/1/09/531 | Instanyl | Liechtenstein | 30.4.2014 |
| EU/1/09/531 | Instanyl | Iceland | 13.5.2014 |
| EU/1/09/532 | Clopidogrel Acino | Iceland | 10.4.2014 |
| EU/1/09/532 | Clopidogrel Acino | Norway | 11.4.2014 |
| EU/1/09/532 | Clopidogrel Acino | Liechtenstein | 30.4.2014 |
| EU/1/09/533 | Vedrop | Norway | 9.5.2014 |
| EU/1/09/533 | Vedrop | Iceland | 22.5.2014 |
| EU/1/09/535 | Grepid | Norway | 28.4.2014 |
| EU/1/09/535 | Grepid | Liechtenstein | 30.4.2014 |
| EU/1/09/535 | Grepid | Iceland | 9.5.2014 |
| EU/1/09/536 | Topotecan Actavis | Iceland | 20.6.2014 |
| EU/1/09/536 | Topotecan Actavis | Norway | 25.6.2014 |
| EU/1/09/536 | Topotecan Actavis | Liechtenstein | 30.6.2014 |
| EU/1/09/537 | Mozobil | Norway | 28.4.2014 |
| EU/1/09/537 | Mozobil | Liechtenstein | 30.4.2014 |
| EU/1/09/537 | Mozobil | Iceland | 9.5.2014 |
| EU/1/09/538 | Afinitor | Iceland | 6.6.2014 |
| EU/1/09/538 | Afinitor | Norway | 18.6.2014 |
| EU/1/09/539 | Samsca | Liechtenstein | 30.6.2014 |
| EU/1/09/540 | Clopidogrel Teva | Norway | 26.5.2014 |
| EU/1/09/540 | Clopidogrel Teva | Iceland | 6.6.2014 |
| EU/1/09/540 | Clopidogrel Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Norway | 3.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Iceland | 6.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Liechtenstein | 30.6.2014 |
| EU/1/09/544 | Cimzia | Iceland | 6.6.2014 |
| EU/1/09/544 | Cimzia | Norway | 18.6.2014 |
| EU/1/09/544 | Cimzia | Liechtenstein | 30.6.2014 |
| EU/1/09/546 | Simponi | Liechtenstein | 30.6.2014 |
| EU/1/09/550 | Javlor | Norway | 18.6.2014 |
| EU/1/09/550 | Javlor | Liechtenstein | 30.6.2014 |
| EU/1/09/551 | Vizarsin | Norway | 26.5.2014 |
| EU/1/09/551 | Vizarsin | Iceland | 6.6.2014 |
| EU/1/09/551 | Vizarsin | Liechtenstein | 30.6.2014 |
| EU/1/09/552 | Topotecan Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/553 | Zyllt | Iceland | 26.5.2014 |
| EU/1/09/553 | Zyllt | Norway | 26.5.2014 |
| EU/1/09/553 | Zyllt | Liechtenstein | 30.6.2014 |
| EU/1/09/555 | Clopidogrel TAD | Liechtenstein | 30.6.2014 |
| EU/1/09/556 | Clopidogrel Krka | Iceland | 26.5.2014 |
| EU/1/09/556 | Clopidogrel Krka | Norway | 26.5.2014 |
| EU/1/09/556 | Clopidogrel Krka | Liechtenstein | 30.6.2014 |
| EU/1/09/558 | Zylagren | Norway | 20.5.2014 |
| EU/1/09/558 | Zylagren | Iceland | 26.5.2014 |
| EU/1/09/558 | Zylagren | Liechtenstein | 30.6.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Iceland | 6.6.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Liechtenstein | 30.6.2014 |
| EU/1/09/560 | Clopidogrel dura | Iceland | 6.6.2014 |
| EU/1/09/560 | Clopidogrel DURA | Liechtenstein | 30.6.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Iceland | 26.5.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Norway | 26.5.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Liechtenstein | 30.6.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Liechtenstein | 30.6.2014 |
| EU/1/09/564 | Ilaris | Liechtenstein | 30.6.2014 |
| EU/1/09/571 | Pandemic Influenza Vaccine H5N1 Baxter | Iceland | 26.5.2014 |
| EU/1/09/571 | Pandemic influenza vaccine H5N1 Baxter | Norway | 26.5.2014 |
| EU/1/09/571 | Pandemic influenza vaccine H5N1 BAXTER | Liechtenstein | 30.6.2014 |
| EU/1/09/581 | Resolor | Iceland | 19.6.2014 |
| EU/1/09/581 | Resolor | Liechtenstein | 30.6.2014 |
| EU/1/10/625 | Arzerra | Norway | 28.1.2014 |
| EU/1/10/625 | Arzerra | Iceland | 12.2.2014 |
| EU/1/10/625 | Arzerra | Liechtenstein | 28.2.2014 |
| EU/1/11/699 | Fampyra | Iceland | 6.6.2014 |
| EU/1/11/699 | Fampyra | Norway | 18.6.2014 |
| EU/1/11/699 | Fampyra | Liechtenstein | 30.6.2014 |
| EU/1/11/749 | Caprelsa | Iceland | 15.1.2014 |
| EU/1/11/749 | Caprelsa | Norway | 20.1.2014 |
| EU/1/11/749 | Caprelsa | Liechtenstein | 28.2.2014 |
| EU/1/12/764 | Pixuvri | Iceland | 7.5.2014 |
| EU/1/12/764 | Pixuvri | Norway | 20.5.2014 |
| EU/1/12/764 | Pixuvri | Liechtenstein | 30.6.2014 |
| EU/1/13/818 | Bosulif | Liechtenstein | 28.2.2014 |
| EU/1/13/818 | Bosulif | Norway | 17.3.2014 |
| EU/1/13/818 | Bosulif | Iceland | 17.3.2014 |
| EU/1/99/103 | ReFacto AF | Iceland | 12.2.2014 |
| EU/1/99/110 | Sustiva | Liechtenstein | 30.4.2014 |
| EU/1/99/110 | Sustiva | Norway | 7.5.2014 |
| EU/1/99/110 | Sustiva | Iceland | 14.5.2014 |
| EU/1/99/111 | Stocrin | Liechtenstein | 30.4.2014 |
| EU/1/99/111 | Stocrin | Norway | 7.5.2014 |
| EU/1/99/111 | Stocrin | Iceland | 14.5.2014 |
| EU/1/99/112 | Ziagen | Iceland | 8.4.2014 |
| EU/1/99/112 | Ziagen | Norway | 15.4.2014 |
| EU/1/99/112 | Ziagen | Liechtenstein | 30.4.2014 |
| EU/1/99/114 | Zeffix | Liechtenstein | 30.6.2014 |
| EU/2/04/042 | Novem | Norway | 14.2.2014 |
| EU/2/04/043 | Equilis StrepE | Iceland | 7.5.2014 |
| EU/2/04/043 | Equilis StrepE | Liechtenstein | 30.6.2014 |
| EU/2/06/070 | Meloxidyl | Norway | 13.2.2014 |
| EU/2/07/071 | Slentrol | Norway | 13.2.2014 |
| EU/2/08/080 | Reconcile | Norway | 13.2.2014 |
| EU/2/08/084 | Trocoxil | Norway | 13.2.2014 |
| EU/2/08/085 | Easotic | Norway | 7.2.2014 |
| EU/2/08/088 | Acticam | Iceland | 6.1.2014 |
| EU/2/08/088 | Acticam | Norway | 29.1.2014 |
| EU/2/08/088 | Acticam | Liechtenstein | 28.2.2014 |
| EU/2/08/089 | Onsior | Norway | 17.3.2014 |
| EU/2/08/090 | Loxicom | Iceland | 19.3.2014 |
| EU/2/08/090 | Loxicom | Norway | 23.4.2014 |
| EU/2/08/090 | Loxicom | Liechtenstein | 30.4.2014 |
| EU/2/08/091 | Porcilis PCV | Iceland | 8.1.2014 |
| EU/2/08/091 | Porcilis PCV | Norway | 13.2.2014 |
| EU/2/08/092 | Startvac | Liechtenstein | 28.2.2014 |
| EU/2/08/092 | Startvac | Iceland | 28.2.2014 |
| EU/2/08/092 | Startvac | Norway | 23.4.2014 |
| EU/2/09/094 | BTVPUR AISap 8 | Iceland | 19.3.2014 |
| EU/2/09/094 | BTVPUR AlSap 8 | Liechtenstein | 30.4.2014 |
| EU/2/09/095 | Improvac | Liechtenstein | 30.4.2014 |
| EU/2/09/095 | Improvac | Iceland | 7.5.2014 |
| EU/2/09/096 | Leucogen | Iceland | 20.6.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Iceland | 19.6.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Liechtenstein | 30.6.2014 |
| EU/2/09/098 | Melovem | Iceland | 20.6.2014 |
| EU/2/09/098 | Melovem | Liechtenstein | 30.6.2014 |
| EU/2/09/099 | Suvaxyn PCV | Iceland | 19.6.2014 |
| EU/2/09/099 | Suvaxyn PCV | Liechtenstein | 30.6.2014 |
| EU/2/98/006 | Nobilis | Norway | 13.2.2014 |
| EU/2/99/014 | Stronghold | Norway | 19.2.2014 |
| EU/2/99/015 | Oxyglobin | Norway | 19.2.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/03/265

Bonviva

Iceland

9.1.2014

EU/1/03/265

Bonviva

Norway

16.1.2014

EU/1/03/265

Bonviva

Liechtenstein

28.2.2014

EU/1/03/271

Advate

Iceland

15.1.2014

EU/1/03/271

Advate

Norway

17.1.2014

EU/1/03/271

Advate

Liechtenstein

28.2.2014

EU/1/04/274

Velcade

Norway

30.1.2014

EU/1/04/274

Velcade

Iceland

5.2.2014

EU/1/04/287

Osseor

Norway

18.6.2014

EU/1/04/287

Osseor

Liechtenstein

30.6.2014

EU/1/04/288

Protelos

Norway

18.6.2014

EU/1/04/288

Protelos

Liechtenstein

30.6.2014

EU/1/04/289

Angiox

Liechtenstein

30.6.2014

EU/1/06/367

Diacomit

Norway

17.1.2014

EU/1/06/367

Diacomit

Iceland

15.1.2014

EU/1/07/423

Vectibix

Liechtenstein

28.2.2014

EU/1/07/423

Vectibix

Norway

17.3.2014

EU/1/07/423

Vectibix

Iceland

17.3.2014

EU/1/07/436

Isentress

Norway

22.5.2014

EU/1/07/436

Isentress

Iceland

26.5.2014

EU/1/07/436

Isentress

Liechtenstein

30.6.2014

EU/1/07/440

Tyverb

Iceland

19.3.2014

EU/1/07/440

Tyverb

Norway

19.3.2014

EU/1/07/440

Tyverb

Liechtenstein

30.4.2014

EU/1/08/497

Nplate

Iceland

14.1.2014

EU/1/08/497

Nplate

Norway

17.1.2014

EU/1/08/497

Nplate

Liechtenstein

28.2.2014

EU/1/08/501

Ixiaro

Iceland

18.3.2014

EU/1/08/501

Ixiaro

Norway

25.3.2014

EU/1/08/501

Ixiaro

Liechtenstein

30.4.2014

EU/1/08/502

Mepact

Iceland

13.1.2014

EU/1/08/502

Mepact

Norway

16.1.2014

EU/1/08/502

Mepact

Liechtenstein

28.2.2014

EU/1/09/508

Synflorix

Liechtenstein

28.2.2014

EU/1/09/508

Synflorix

Iceland

18.3.2014

EU/1/09/508

Synflorix

Norway

24.3.2014

EU/1/09/509

Ribavirin Teva

Norway

29.1.2014

EU/1/09/509

Ribavirin Teva

Iceland

6.2.2014

EU/1/09/509

Ribavirin Teva

Liechtenstein

28.2.2014

EU/1/09/510

Fertavid

Liechtenstein

28.2.2014

EU/1/09/510

Fertavid

Norway

17.3.2014

EU/1/09/510

Fertavid

Iceland

18.3.2014

EU/1/09/511

Conbriza

Norway

17.3.2014

EU/1/09/512

Removab

Iceland

10.1.2014

EU/1/09/512

Removab

Norway

20.1.2014

EU/1/09/512

Removab

Liechtenstein

28.2.2014

EU/1/09/514

Zebinix

Norway

3.2.2014

EU/1/09/514

Zebinix

Iceland

5.2.2014

EU/1/09/514

Zebinix

Liechtenstein

28.2.2014

EU/1/09/515

CONTROLOC Control

Liechtenstein

28.2.2014

EU/1/09/515

CONTROLOC Control

Iceland

18.3.2014

EU/1/09/515

Controloc Control

Norway

20.3.2014

EU/1/09/516

SOMAC Control

Liechtenstein

28.2.2014

EU/1/09/516

SOMAC Control

Iceland

18.3.2014

EU/1/09/516

Somac Control

Norway

20.3.2014

EU/1/09/517

PANTOZOL Control

Liechtenstein

28.2.2014

EU/1/09/517

PANTOZOL Control

Iceland

18.3.2014

EU/1/09/517

Pantozol Control

Norway

20.3.2014

EU/1/09/518

PANTECTA Control

Liechtenstein

28.2.2014

EU/1/09/518

PANTECTA Control

Iceland

18.3.2014

EU/1/09/518

Pantecta Control

Norway

20.3.2014

EU/1/09/519

PANTOLOC Control

Liechtenstein

28.2.2014

EU/1/09/519

PANTOLOC Control

Iceland

18.3.2014

EU/1/09/519

Pantoloc Control

Norway

20.3.2014

EU/1/09/521

Renvela

Iceland

10.4.2014

EU/1/09/521

Renvela

Norway

23.4.2014

EU/1/09/521

Renvela

Liechtenstein

30.4.2014

EU/1/09/522

ellaOne

Iceland

10.4.2014

EU/1/09/522

ellaOne

Norway

25.4.2014

EU/1/09/522

ellaOne

Liechtenstein

30.4.2014

EU/1/09/523

Modigraf

Liechtenstein

28.2.2014

EU/1/09/523

Modigraf

Iceland

12.3.2014

EU/1/09/523

Modigraf

Norway

17.3.2014

EU/1/09/524

Qutenza

Liechtenstein

30.4.2014

EU/1/09/524

Qutenza

Norway

9.5.2014

EU/1/09/524

Qutenza

Iceland

14.5.2014

EU/1/09/525

Nimvastid

Norway

29.1.2014

EU/1/09/525

Nimvastid

Iceland

5.2.2014

EU/1/09/525

Nimvastid

Liechtenstein

28.2.2014

EU/1/09/526

Iressa

Iceland

9.5.2014

EU/1/09/526

Iressa

Norway

20.5.2014

EU/1/09/526

Iressa

Liechtenstein

30.6.2014

EU/1/09/527

Ribavirin Teva Pharma BV

Norway

29.1.2014

EU/1/09/527

Ribavirin Teva Pharma B.V.

Iceland

6.2.2014

EU/1/09/528

Peyona

Norway

17.3.2014

EU/1/09/528

Peyona

Iceland

19.3.2014

EU/1/09/528

Peyona

Liechtenstein

30.4.2014

EU/1/09/529

Victoza

Norway

25.4.2014

EU/1/09/529

Victoza

Liechtenstein

30.4.2014

EU/1/09/529

Victoza

Iceland

9.5.2014

EU/1/09/530

Repaglinide Teva

Liechtenstein

30.6.2014

EU/1/09/531

Instanyl

Norway

29.4.2014

EU/1/09/531

Instanyl

Liechtenstein

30.4.2014

EU/1/09/531

Instanyl

Iceland

13.5.2014

EU/1/09/532

Clopidogrel Acino

Iceland

10.4.2014

EU/1/09/532

Clopidogrel Acino

Norway

11.4.2014

EU/1/09/532

Clopidogrel Acino

Liechtenstein

30.4.2014

EU/1/09/533

Vedrop

Norway

9.5.2014

EU/1/09/533

Vedrop

Iceland

22.5.2014

EU/1/09/535

Grepid

Norway

28.4.2014

EU/1/09/535

Grepid

Liechtenstein

30.4.2014

EU/1/09/535

Grepid

Iceland

9.5.2014

EU/1/09/536

Topotecan Actavis

Iceland

20.6.2014

EU/1/09/536

Topotecan Actavis

Norway

25.6.2014

EU/1/09/536

Topotecan Actavis

Liechtenstein

30.6.2014

EU/1/09/537

Mozobil

Norway

28.4.2014

EU/1/09/537

Mozobil

Liechtenstein

30.4.2014

EU/1/09/537

Mozobil

Iceland

9.5.2014

EU/1/09/538

Afinitor

Iceland

6.6.2014

EU/1/09/538

Afinitor

Norway

18.6.2014

EU/1/09/539

Samsca

Liechtenstein

30.6.2014

EU/1/09/540

Clopidogrel Teva

Norway

26.5.2014

EU/1/09/540

Clopidogrel Teva

Iceland

6.6.2014

EU/1/09/540

Clopidogrel Teva

Liechtenstein

30.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Norway

3.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Iceland

6.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Liechtenstein

30.6.2014

EU/1/09/544

Cimzia

Iceland

6.6.2014

EU/1/09/544

Cimzia

Norway

18.6.2014

EU/1/09/544

Cimzia

Liechtenstein

30.6.2014

EU/1/09/546

Simponi

Liechtenstein

30.6.2014

EU/1/09/550

Javlor

Norway

18.6.2014

EU/1/09/550

Javlor

Liechtenstein

30.6.2014

EU/1/09/551

Vizarsin

Norway

26.5.2014

EU/1/09/551

Vizarsin

Iceland

6.6.2014

EU/1/09/551

Vizarsin

Liechtenstein

30.6.2014

EU/1/09/552

Topotecan Teva

Liechtenstein

30.6.2014

EU/1/09/553

Zyllt

Iceland

26.5.2014

EU/1/09/553

Zyllt

Norway

26.5.2014

EU/1/09/553

Zyllt

Liechtenstein

30.6.2014

EU/1/09/555

Clopidogrel TAD

Liechtenstein

30.6.2014

EU/1/09/556

Clopidogrel Krka

Iceland

26.5.2014

EU/1/09/556

Clopidogrel Krka

Norway

26.5.2014

EU/1/09/556

Clopidogrel Krka

Liechtenstein

30.6.2014

EU/1/09/558

Zylagren

Norway

20.5.2014

EU/1/09/558

Zylagren

Iceland

26.5.2014

EU/1/09/558

Zylagren

Liechtenstein

30.6.2014

EU/1/09/559

Clopidogrel Mylan

Iceland

6.6.2014

EU/1/09/559

Clopidogrel Mylan

Liechtenstein

30.6.2014

EU/1/09/560

Clopidogrel dura

Iceland

6.6.2014

EU/1/09/560

Clopidogrel DURA

Liechtenstein

30.6.2014

EU/1/09/561

Clopidogrel Teva Pharma

Iceland

26.5.2014

EU/1/09/561

Clopidogrel Teva Pharma

Norway

26.5.2014

EU/1/09/561

Clopidogrel Teva Pharma

Liechtenstein

30.6.2014

EU/1/09/562

Clopidogrel Krka d.d.

Liechtenstein

30.6.2014

EU/1/09/564

Ilaris

Liechtenstein

30.6.2014

EU/1/09/571

Pandemic Influenza Vaccine H5N1 Baxter

Iceland

26.5.2014

EU/1/09/571

Pandemic influenza vaccine H5N1 Baxter

Norway

26.5.2014

EU/1/09/571

Pandemic influenza vaccine H5N1 BAXTER

Liechtenstein

30.6.2014

EU/1/09/581

Resolor

Iceland

19.6.2014

EU/1/09/581

Resolor

Liechtenstein

30.6.2014

EU/1/10/625

Arzerra

Norway

28.1.2014

EU/1/10/625

Arzerra

Iceland

12.2.2014

EU/1/10/625

Arzerra

Liechtenstein

28.2.2014

EU/1/11/699

Fampyra

Iceland

6.6.2014

EU/1/11/699

Fampyra

Norway

18.6.2014

EU/1/11/699

Fampyra

Liechtenstein

30.6.2014

EU/1/11/749

Caprelsa

Iceland

15.1.2014

EU/1/11/749

Caprelsa

Norway

20.1.2014

EU/1/11/749

Caprelsa

Liechtenstein

28.2.2014

EU/1/12/764

Pixuvri

Iceland

7.5.2014

EU/1/12/764

Pixuvri

Norway

20.5.2014

EU/1/12/764

Pixuvri

Liechtenstein

30.6.2014

EU/1/13/818

Bosulif

Liechtenstein

28.2.2014

EU/1/13/818

Bosulif

Norway

17.3.2014

EU/1/13/818

Bosulif

Iceland

17.3.2014

EU/1/99/103

ReFacto AF

Iceland

12.2.2014

EU/1/99/110

Sustiva

Liechtenstein

30.4.2014

EU/1/99/110

Sustiva

Norway

7.5.2014

EU/1/99/110

Sustiva

Iceland

14.5.2014

EU/1/99/111

Stocrin

Liechtenstein

30.4.2014

EU/1/99/111

Stocrin

Norway

7.5.2014

EU/1/99/111

Stocrin

Iceland

14.5.2014

EU/1/99/112

Ziagen

Iceland

8.4.2014

EU/1/99/112

Ziagen

Norway

15.4.2014

EU/1/99/112

Ziagen

Liechtenstein

30.4.2014

EU/1/99/114

Zeffix

Liechtenstein

30.6.2014

EU/2/04/042

Novem

Norway

14.2.2014

EU/2/04/043

Equilis StrepE

Iceland

7.5.2014

EU/2/04/043

Equilis StrepE

Liechtenstein

30.6.2014

EU/2/06/070

Meloxidyl

Norway

13.2.2014

EU/2/07/071

Slentrol

Norway

13.2.2014

EU/2/08/080

Reconcile

Norway

13.2.2014

EU/2/08/084

Trocoxil

Norway

13.2.2014

EU/2/08/085

Easotic

Norway

7.2.2014

EU/2/08/088

Acticam

Iceland

6.1.2014

EU/2/08/088

Acticam

Norway

29.1.2014

EU/2/08/088

Acticam

Liechtenstein

28.2.2014

EU/2/08/089

Onsior

Norway

17.3.2014

EU/2/08/090

Loxicom

Iceland

19.3.2014

EU/2/08/090

Loxicom

Norway

23.4.2014

EU/2/08/090

Loxicom

Liechtenstein

30.4.2014

EU/2/08/091

Porcilis PCV

Iceland

8.1.2014

EU/2/08/091

Porcilis PCV

Norway

13.2.2014

EU/2/08/092

Startvac

Liechtenstein

28.2.2014

EU/2/08/092

Startvac

Iceland

28.2.2014

EU/2/08/092

Startvac

Norway

23.4.2014

EU/2/09/094

BTVPUR AISap 8

Iceland

19.3.2014

EU/2/09/094

BTVPUR AlSap 8

Liechtenstein

30.4.2014

EU/2/09/095

Improvac

Liechtenstein

30.4.2014

EU/2/09/095

Improvac

Iceland

7.5.2014

EU/2/09/096

Leucogen

Iceland

20.6.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Iceland

19.6.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Liechtenstein

30.6.2014

EU/2/09/098

Melovem

Iceland

20.6.2014

EU/2/09/098

Melovem

Liechtenstein

30.6.2014

EU/2/09/099

Suvaxyn PCV

Iceland

19.6.2014

EU/2/09/099

Suvaxyn PCV

Liechtenstein

30.6.2014

EU/2/98/006

Nobilis

Norway

13.2.2014

EU/2/99/014

Stronghold

Norway

19.2.2014

EU/2/99/015

Oxyglobin

Norway

19.2.2014

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/5/320 | Noxafil | Norway | 21.5.2014 |
| EU/1/5/320/002-003 | Noxafil | Iceland | 14.5.2014 |
| EU/1/08/492 | RoActemra | Norway | 19.5.2014 |
| EU/1/08/492/007 | RoActemra | Iceland | 22.5.2014 |
| EU/1/11/710/009-015 | Votubia | Iceland | 20.1.2014 |
| EU/1/13/825 | Imatinib Actavis | Norway | 23.6.2014 |
| EU/1/13/825/020-023 | Imatinib Actavis | Iceland | 27.6.2014 |
| EU/1/98/067 | MabThera | Norway | 11.4.2014 |
| EU/1/98/067/003 | MabThera | Iceland | 9.4.2014 |
| EU/2/04/044 | Aivlosin | Norway | 17.3.2014 |
| EU/2/09/098 | Melovem | Norway | 11.2.2014 |
| EU/2/10/115 | Comfortis | Norway | 29.1.2014 |
| EU/2/12/144 | Contacera | Norway | 21.3.2014 |
| EU/2/12/144/05-006 | Contacera | Iceland | 12.3.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/5/320

Noxafil

Norway

21.5.2014

EU/1/5/320/002-003

Noxafil

Iceland

14.5.2014

EU/1/08/492

RoActemra

Norway

19.5.2014

EU/1/08/492/007

RoActemra

Iceland

22.5.2014

EU/1/11/710/009-015

Votubia

Iceland

20.1.2014

EU/1/13/825

Imatinib Actavis

Norway

23.6.2014

EU/1/13/825/020-023

Imatinib Actavis

Iceland

27.6.2014

EU/1/98/067

MabThera

Norway

11.4.2014

EU/1/98/067/003

MabThera

Iceland

9.4.2014

EU/2/04/044

Aivlosin

Norway

17.3.2014

EU/2/09/098

Melovem

Norway

11.2.2014

EU/2/10/115

Comfortis

Norway

29.1.2014

EU/2/12/144

Contacera

Norway

21.3.2014

EU/2/12/144/05-006

Contacera

Iceland

12.3.2014

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/153 | Infanrix Penta | Iceland | 22.1.2014 |
| EU/1/06/339 | Preotact | Liechtenstein | 30.6.2014 |
| EU/1/06/349 | Avaglim | Iceland | 21.1.2014 |
| EU/1/06/381 | Daronrix | Iceland | 21.1.2014 |
| EU/1/09/554 | Clopidogrel ratiopharm | Iceland | 21.1.2014 |
| EU/1/09/554 | Clopidogrel ratiopharm | Norway | 11.2.2014 |
| EU/1/10/626 | Ribavirin BioPartners | Iceland | 24.1.2014 |
| EU/1/11/729 | Onduarp | Liechtenstein | 28.2.2014 |
| EU/1/11/729 | Onduarp | Iceland | 12.3.2014 |
| EU/1/11/729 | Onduarp | Norway | 27.3.2014 |
| EU/1/96/014 | Tritanrix HepB | Iceland | 7.2.2014 |
| EU/1/97/54 | Viracept | Iceland | 24.1.2014 |
| EU/2/00/022 | Ibaflin | Iceland | 21.1.2014 |
| EU/2/06/58 | Flexicam | Liechtenstein | 30.6.2014 |
| EU/2/06/58 | Flexicam | Norway | 3.6.2014 |
| EU/2/09/093 | Netvax | Norway | 7.1.2014 |

EU Number

Product

Country

Date of withdrawal

EU/1/00/153

Infanrix Penta

Iceland

22.1.2014

EU/1/06/339

Preotact

Liechtenstein

30.6.2014

EU/1/06/349

Avaglim

Iceland

21.1.2014

EU/1/06/381

Daronrix

Iceland

21.1.2014

EU/1/09/554

Clopidogrel ratiopharm

Iceland

21.1.2014

EU/1/09/554

Clopidogrel ratiopharm

Norway

11.2.2014

EU/1/10/626

Ribavirin BioPartners

Iceland

24.1.2014

EU/1/11/729

Onduarp

Liechtenstein

28.2.2014

EU/1/11/729

Onduarp

Iceland

12.3.2014

EU/1/11/729

Onduarp

Norway

27.3.2014

EU/1/96/014

Tritanrix HepB

Iceland

7.2.2014

EU/1/97/54

Viracept

Iceland

24.1.2014

EU/2/00/022

Ibaflin

Iceland

21.1.2014

EU/2/06/58

Flexicam

Liechtenstein

30.6.2014

EU/2/06/58

Flexicam

Norway

3.6.2014

EU/2/09/093

Netvax

Norway

7.1.2014

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/06/361 | Luminity | Liechtenstein | 28.2.2014 |
| EU/1/11/75 | Vibativ | Liechtenstein | 30.4.2014 |

EU-Number

Product

Country

Date of suspension

EU/1/06/361

Luminity

Liechtenstein

28.2.2014

EU/1/11/75

Vibativ

Liechtenstein

30.4.2014

---